Table 3.
Changes in calcitonin and CEA during treatment.
| Patient | Level at baseline | Maximum reduction (%) | Level at study exit | Increase from baseline till study exit (%) |
Best response | |
|---|---|---|---|---|---|---|
| 1 | CT (pmol/L) | 73900 | — | 77700 | 105,1 | SD |
| CEA (µg/L) | 246,5 | — | 353,3 | 143,3 | ||
|
| ||||||
| 2 | CT (pmol/L) | 245 | — | 280 | 114,3 | SD |
| CEA (µg/L) | 354,3 | — | 2208,0 | 623,2 | ||
|
| ||||||
| 3 | CT (pmol/L) | 6750 | — | 29800 | 441,4 | PD |
| CEA (µg/L) | 1477,0 | — | 2081,0 | 140,9 | ||
|
| ||||||
| 4 | CT (pmol/L) | 12716 | 30,3 | 8869 | ‡ | PD |
| CEA (µg/L) | 216,9 | 4,9 | 247,9 | 114,3 | ||
|
| ||||||
| 5 | CT (pmol/L) | 680 | 37,3 | 1148 | 168,8 | SD |
| CEA (µg/L) | 117,1 | — | 164,4 | 140,4 | ||
|
| ||||||
| 6 | CT (pmol/L) | 58 | 56,9 | 89 | 153,4 | SD |
| CEA (µg/L) | 70,7 | 35,5 | 86,7 | 122,6 | ||
|
| ||||||
| 7 | CT (pmol/L) | 2156 | — | 5239+ | 243+ | SD |
| CEA (µg/L) | 91,1 | 10,1 | 166,7+ | 183+ | ||
CT: calcitonin and CEA: carcinoembryonic antigen level.
—: there was no reduction in CT or CEA compared to baseline and ‡: there was no increase in CT compared to baseline; +patient is still on everolimus treatment.